The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | AMG 673: novel half-life extended anti-CD33/CD3 BiTE in R/R AML
Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, discusses the preliminary results from a phase I first-in-human study (NCT03224819) of AMG 673, a novel half-life extended anti-CD33/CD3 bispecific T-cell engager (BiTE) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Prof. Subklewe explains that the most common treatment-related adverse event was cytokine release syndrome (CRS). Additionally, assessment of bone marrow in treated patients showed a decrease in blasts and dose-related increases in Cmax and AUC were observed following AMG 673 infusions. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
